BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21420571)

  • 1. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
    Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug interactions in critically-ill patients. An important factor in the use of micafungin?].
    Garnacho-Montero J; Jiménez Parrilla F
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():33-7. PubMed ID: 21420575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Why might micafungin be the drug of choice in pediatric patients?].
    Ramos Amador JT; Prieto Tato L; Guillén Martín S
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacodynamics and pharmacokinetics of micafungin in adults, children and neonate].
    Catalán-González M; Carlos Montejo-González J
    Rev Iberoam Micol; 2009 Mar; 26(1):23-34. PubMed ID: 19463274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.
    Cornely OA; Pappas PG; Young JA; Maddison P; Ullmann AJ
    Expert Opin Drug Saf; 2011 Mar; 10(2):171-83. PubMed ID: 21306282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Micafungin for therapy of invasive candidiasis in solid organ transplant recipients].
    Fortún-Abete J
    Rev Iberoam Micol; 2009 Mar; 26(1):65-8. PubMed ID: 19463280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections.
    Cross SA; Scott LJ
    Drugs; 2008; 68(15):2225-55. PubMed ID: 18840009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.
    Carter NJ; Keating GM
    Paediatr Drugs; 2009; 11(4):271-91. PubMed ID: 19566111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of micafungin in pediatric clinical trials.
    Arrieta AC; Maddison P; Groll AH
    Pediatr Infect Dis J; 2011 Jun; 30(6):e97-e102. PubMed ID: 21378595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].
    Montejo M; Quindós G
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():15-22. PubMed ID: 21420572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis.
    Benjamin DK; Deville JG; Azie N; Kovanda L; Roy M; Wu C; Arrieta A
    Pediatr Infect Dis J; 2013 Nov; 32(11):e419-25. PubMed ID: 23958810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.
    Auriti C; Falcone M; Ronchetti MP; Goffredo BM; Cairoli S; Crisafulli R; Piersigilli F; Corsetti T; Dotta A; Pai MP
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7333-7339. PubMed ID: 27697761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation.
    Albano E; Azie N; Roy M; Townsend R; Arrieta A
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e45-50. PubMed ID: 25072363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antifungal therapy update: new drugs and medical uses].
    Fortún J
    Enferm Infecc Microbiol Clin; 2011 Dec; 29 Suppl 5():38-44. PubMed ID: 22305668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
    Salavert M; Jarque I
    Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia.
    Undre NA; Stevenson P; Freire A; Arrieta A
    Pediatr Infect Dis J; 2012 Jun; 31(6):630-2. PubMed ID: 22301478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.